| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Patricia L Brubake. Incretin-based therapies: mimetics versus protease inhibitors. Trends in endocrinology and metabolism: TEM. vol 18. issue 6. 2007-10-12. PMID:17629492. |
the physiological incretins, glucose-dependent insulinotropic polypeptide (gip) and glucagon-like peptide-1 (glp-1), lower blood glucose levels through multiple mechanisms, including enhancement of glucose-stimulated insulin secretion. |
2007-10-12 |
2023-08-12 |
Not clear |
| Alissa K Langley, Terri J Suffoletta, Heath R Jenning. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus. Pharmacotherapy. vol 27. issue 8. 2007-10-11. PMID:17655515. |
unlike conventional oral antidiabetic agents, these agents promote glucose homeostasis through inhibition of dpp-iv, the enzyme responsible for degradation of two key glucoregulatory hormones: glucagon-like peptide-1 (glp-1), which extends the action of insulin while also suppressing the release of glucagon, and glucose-dependent insulinotropic peptide (gip). |
2007-10-11 |
2023-08-12 |
Not clear |
| Jie Zhou, Mauren F A Livak, Michel Bernier, Denis C Muller, Olga D Carlson, Dariush Elahi, Stuart Maudsley, Josephine M Ega. Ubiquitination is involved in glucose-mediated downregulation of GIP receptors in islets. American journal of physiology. Endocrinology and metabolism. vol 293. issue 2. 2007-09-24. PMID:17505054. |
glucose-dependent insulinotropic polypeptide (gip) is a gastrointestinal hormone that has a potent stimulatory effect on insulin release under conditions of normal glucose tolerance. |
2007-09-24 |
2023-08-12 |
human |
| A A Palizban, R Salehi, N Nori, H Galehdar. In vivo transfection rat small intestine K-cell with pGIP/Ins plasmid by DOTAP liposome. Journal of drug targeting. vol 15. issue 5. 2007-08-27. PMID:17541844. |
the potential of the transmission of a constructed plasmid, which contains human insulin gene under the control of gip promoter, to gut k-cells could be considered for treatment of diabetes. |
2007-08-27 |
2023-08-12 |
human |
| J F Todd, S R Bloo. Incretins and other peptides in the treatment of diabetes. Diabetic medicine : a journal of the British Diabetic Association. vol 24. issue 3. 2007-08-13. PMID:17263764. |
together with glucose-dependent insulinotropic polypeptide (gip), it is responsible for the incretin effect which is the augmentation of insulin secretion following oral administration of glucose. |
2007-08-13 |
2023-08-12 |
human |
| Finbarr P M O'Harte, Kerry Hunter, Victor A Gault, Nigel Irwin, Brian D Green, Brett Greer, Patrick Harriott, Clifford J Bailey, Peter R Flat. Antagonistic effects of two novel GIP analogs, (Hyp3)GIP and (Hyp3)GIPLys16PAL, on the biological actions of GIP and longer-term effects in diabetic ob/ob mice. American journal of physiology. Endocrinology and metabolism. vol 292. issue 6. 2007-07-30. PMID:17299087. |
all three peptides exhibited dpp iv resistance, and significantly inhibited gip stimulated camp formation and insulin secretion in gip receptor-transfected fibroblasts and in clonal pancreatic brin-bd11 cells, respectively. |
2007-07-30 |
2023-08-12 |
mouse |
| Finbarr P M O'Harte, Kerry Hunter, Victor A Gault, Nigel Irwin, Brian D Green, Brett Greer, Patrick Harriott, Clifford J Bailey, Peter R Flat. Antagonistic effects of two novel GIP analogs, (Hyp3)GIP and (Hyp3)GIPLys16PAL, on the biological actions of GIP and longer-term effects in diabetic ob/ob mice. American journal of physiology. Endocrinology and metabolism. vol 292. issue 6. 2007-07-30. PMID:17299087. |
administration of once daily injections of (hyp(3))gip or (hyp(3))giplys(16)pal for 14 days resulted in significantly lower plasma glucose levels (p < 0.05) after (hyp(3))gip on days 12 and 14 and enhanced glucose tolerance (p < 0.05) and insulin sensitivity (p < 0.05 to p < 0.001) in both groups by day 14. |
2007-07-30 |
2023-08-12 |
mouse |
| Finbarr P M O'Harte, Kerry Hunter, Victor A Gault, Nigel Irwin, Brian D Green, Brett Greer, Patrick Harriott, Clifford J Bailey, Peter R Flat. Antagonistic effects of two novel GIP analogs, (Hyp3)GIP and (Hyp3)GIPLys16PAL, on the biological actions of GIP and longer-term effects in diabetic ob/ob mice. American journal of physiology. Endocrinology and metabolism. vol 292. issue 6. 2007-07-30. PMID:17299087. |
both (hyp(3))gip and (hyp(3))giplys(16)pal treatment also reduced pancreatic insulin (p < 0.05 to p < 0.01) without affecting islet number. |
2007-07-30 |
2023-08-12 |
mouse |
| Nigel Irwin, Paula L McClean, Peter R Flat. Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice. Journal of peptide science : an official publication of the European Peptide Society. vol 13. issue 6. 2007-07-10. PMID:17486662. |
glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip) are the two key incretin hormones released from the gastrointestinal tract that regulate blood glucose homeostasis through potent insulin secretion. |
2007-07-10 |
2023-08-12 |
mouse |
| Victor A Gault, Kerry Hunter, Nigel Irwin, Brian D Green, Brett Greer, Patrick Harriott, Finbarr P M O'Harte, Peter R Flat. Characterisation and biological activity of Glu3 amino acid substituted GIP receptor antagonists. Archives of biochemistry and biophysics. vol 461. issue 2. 2007-06-26. PMID:17428436. |
glucose-dependent insulinotropic polypeptide (gip) is an important gastrointestinal hormone, which regulates insulin release and glucose homeostasis, but is rapidly inactivated by enzymatic n-terminal truncation. |
2007-06-26 |
2023-08-12 |
mouse |
| Victor A Gault, Kerry Hunter, Nigel Irwin, Brian D Green, Brett Greer, Patrick Harriott, Finbarr P M O'Harte, Peter R Flat. Characterisation and biological activity of Glu3 amino acid substituted GIP receptor antagonists. Archives of biochemistry and biophysics. vol 461. issue 2. 2007-06-26. PMID:17428436. |
in brin-bd11 cells, (lys(3))gip, (phe(3))gip, (trp(3))gip and (tyr(3))gip did not stimulate insulin secretion with both (lys(3))gip and (phe(3))gip significantly inhibiting gip-stimulated insulin secretion (p<0.05). |
2007-06-26 |
2023-08-12 |
mouse |
| Victor A Gault, Kerry Hunter, Nigel Irwin, Brian D Green, Brett Greer, Patrick Harriott, Finbarr P M O'Harte, Peter R Flat. Characterisation and biological activity of Glu3 amino acid substituted GIP receptor antagonists. Archives of biochemistry and biophysics. vol 461. issue 2. 2007-06-26. PMID:17428436. |
(ala(3))gip, (phe(3))gip and (tyr(3))gip, when administered together with gip, significantly reduced plasma insulin (p<0.05 to p<0.01) and impaired the glucose-lowering ability (p<0.05 to p<0.01) of the native peptide. |
2007-06-26 |
2023-08-12 |
mouse |
| Gang Xu, Hideaki Kaneto, D Ross Laybutt, Valerie F Duvivier-Kali, Nitin Trivedi, Kiyoshi Suzuma, George L King, Gordon C Weir, Susan Bonner-Wei. Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes. Diabetes. vol 56. issue 6. 2007-06-14. PMID:17360984. |
stimulation of insulin secretion by the incretin hormones glucagon-like peptide 1 (glp-1) and glucose-dependent insulinotropic peptide (gip) has been found to be diminished in type 2 diabetes. |
2007-06-14 |
2023-08-12 |
rat |
| Gang Xu, Hideaki Kaneto, D Ross Laybutt, Valerie F Duvivier-Kali, Nitin Trivedi, Kiyoshi Suzuma, George L King, Gordon C Weir, Susan Bonner-Wei. Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes. Diabetes. vol 56. issue 6. 2007-06-14. PMID:17360984. |
perifused islets isolated from hyperglycemic px rats showed reduced insulin responses to glp-1 and gip. |
2007-06-14 |
2023-08-12 |
rat |
| Alpeshkumar K Malde, Sudha S Srivastava, Evans C Coutinh. Understanding interactions of gastric inhibitory polypeptide (GIP) with its G-protein coupled receptor through NMR and molecular modeling. Journal of peptide science : an official publication of the European Peptide Society. vol 13. issue 5. 2007-06-01. PMID:17437246. |
gastric inhibitory polypeptide (gip, or glucose-dependent insulinotropic polypeptide) is a 42-amino acid incretin hormone moderating glucose-induced insulin secretion. |
2007-06-01 |
2023-08-12 |
cattle |
| Reawika Chaikomin, Keng Liang Wu, Selena Doran, Karen L Jones, Andre J P M Smout, Willem Renooij, Richard H Holloway, James H Meyer, Michael Horowitz, Christopher K Rayne. Concurrent duodenal manometric and impedance recording to evaluate the effects of hyoscine on motility and flow events, glucose absorption, and incretin release. American journal of physiology. Gastrointestinal and liver physiology. vol 292. issue 4. 2007-05-17. PMID:17204542. |
concurrently, glucose and 3-o-methylglucose (3-omg) were infused into the proximal duodenum (3 kcal/min), with frequent blood sampling to measure glucose, 3-omg, insulin, glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip). |
2007-05-17 |
2023-08-12 |
human |
| Reawika Chaikomin, Keng Liang Wu, Selena Doran, Karen L Jones, Andre J P M Smout, Willem Renooij, Richard H Holloway, James H Meyer, Michael Horowitz, Christopher K Rayne. Concurrent duodenal manometric and impedance recording to evaluate the effects of hyoscine on motility and flow events, glucose absorption, and incretin release. American journal of physiology. Gastrointestinal and liver physiology. vol 292. issue 4. 2007-05-17. PMID:17204542. |
overall, blood glucose (p<0.01) and plasma 3-omg concentrations (p<0.05) were lower during hyoscine than saline, whereas plasma insulin, glp-1, and gip concentrations were initially (t=20 min) lower during hyoscine (p<0.05). |
2007-05-17 |
2023-08-12 |
human |
| Su-Jin Kim, Cuilan Nian, Christopher H S McIntos. Activation of lipoprotein lipase by glucose-dependent insulinotropic polypeptide in adipocytes. A role for a protein kinase B, LKB1, and AMP-activated protein kinase cascade. The Journal of biological chemistry. vol 282. issue 12. 2007-05-02. PMID:17244606. |
in differentiated 3t3-l1 adipocytes, gip, in the presence of insulin, increased lpl activity and triglyceride accumulation through a pathway involving increased phosphorylation of protein kinase b (pkb) and reductions in phosphorylated lkb1 and amp-activated protein kinase (ampk). |
2007-05-02 |
2023-08-12 |
human |
| Baptist Gallwit. Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes. Drugs of today (Barcelona, Spain : 1998). vol 43. issue 1. 2007-05-01. PMID:17315049. |
glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic peptide (gip) are important incretin hormones contributing to 50-70% of the stimulation of insulin secretion after a meal. |
2007-05-01 |
2023-08-12 |
Not clear |
| Victor A Gault, Kerry Hunter, Nigel Irwin, Brett Greer, Brian D Green, Patrick Harriott, Finbarr P M O'Harte, Peter R Flat. Characterisation and glucoregulatory actions of a novel acylated form of the (Pro3)GIP receptor antagonist in type 2 diabetes. Biological chemistry. vol 388. issue 2. 2007-04-06. PMID:17261080. |
like the parent molecule (pro3)gip, (pro3)giplys16pal was completely stable to the actions of dpp-iv and significantly (p<0.01 to p<0.001) inhibited gip-stimulated camp production and cellular insulin secretion. |
2007-04-06 |
2023-08-12 |
mouse |